LB-54640 is under clinical development by Rhythm Pharmaceuticals and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LB-54640’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LB-54640 overview

LB-54640 is under development for the treatment of genetic obesity. It is administered by the oral route. It acts by targeting MC4R.

Rhythm Pharmaceuticals overview

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company. It develops therapies for the treatment of rare genetic diseases of obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin and kexin type 1 (PCSK1) and leptin receptor (LEPR) deficiency. The company’s lead drug IMCIVREE (setmelanotide), is a precision medicine to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases. It is advancing RM-853, a ghrelin O-acyltransferase (GOAT) inhibitor targeting prader-willi syndrome. The company operates in the UK, Ireland, France, Italy, Canada, the US and the Netherlands, among others. Rhythm Pharma is headquartered in Boston, Massachusetts, the US.

For a complete picture of LB-54640’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.